Physician profile
Michael J Brody
NPI 1407948110
$1,955.47
in general payments reported to CMS, 2019-2025
21 companies · $518 in 2025
The $518 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $14.63 · 2022: $203 · 2023: $488 · 2024: $339 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327 · Education: $18.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.69 |
| Education | $18.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.23 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $362.43 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Pfizer INC. | $311.41 | 2019-2025 | |
| Celgene Corporation | $196.59 | 2022-2024 | Zeposia |
| Genzyme Corporation | $151.39 | 2025 | |
| Aimmune Therapeutics, INC. | $67.45 | 2025 | Zenpep |
| Intra-Sana Laboratories | $63.85 | 2022-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Intercept Pharmaceuticals, INC. | $58.58 | 2023-2025 | Ocaliva |
| Ucb, INC. | $49.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $44.20 | 2023 | Dupixent |
| Boston Scientific Corporation | $32.87 | 2024 | Wavewriter Alpha Prime 16 |
| Ardelyx, INC. | $24.33 | 2023 | Ibsrela |
| Janssen Pharmaceuticals, INC | $23.13 | 2019 | |
| Celltrion USA INC. | $18.41 | 2023 | Yuflyma |
| Cumberland Pharmaceuticals, INC. | $18.16 | 2024 | Sancuso |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.26 | 2022 | |
| Merck Sharp & Dohme LLC | $15.20 | 2024 | Dificid |
| Ferring Pharmaceuticals INC. | $14.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.63 | 2020 | |
| Braintree Laboratories, INC. | $14.58 | 2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.